Anebulo Pharmaceuticals

Anebulo Pharmaceuticals is focused on developing novel therapeutics for substance use disorders, with an immediate priority on acute cannabinoid intoxication. The company has achieved Phase 2 proof-of-concept for its lead candidate, ANEB-001, demonstrating its potential to rapidly reverse THC-induced effects. Anebulo's strategy capitalizes on the urgent, growing medical need created by increasing cannabis legalization and the lack of any approved antidote, positioning it to target emergency department visits and unintentional pediatric poisonings.

Platform centered on small molecule antagonists of the cannabinoid CB1 receptor, designed for rapid reversal of intoxication with oral bioavailability and brain penetration.

Anebulo operates in a near-vacant competitive space with no FDA-approved specific antidote for cannabinoid intoxication. Current standard of care is non-specific supportive management. The company's lead candidate, ANEB-001, holds a substantial first-mover advantage in clinical development.